OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Show more
35a Albemarle St, London, W1S 4JE, United Kingdom
Market Cap
82.39M
52 Wk Range
$1.34 - $3.20
Previous Close
$1.55
Open
$1.55
Volume
32,935
Day Range
$1.52 - $1.60
Enterprise Value
75.21M
Cash
20.59M
Avg Qtr Burn
N/A
Insider Ownership
31.03%
Institutional Own.
20.12%
Qtr Updated
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Urcosimod (OK-101) Details Neuropathic Corneal Pain (NCP) | Phase 3 Initiation |